IBTA Ibotta, Inc. Insider Trading

Clark Jermoluk Founders Fund I LLC sells 500,000 shares (3.34M post) of IBTA at $30.15; 5 of 5 prior IBTA sells well-timed with -23.5% to -45.8% 90d returns.

Clark Jermoluk Founders Fund I LLC, a 10% owner, sold 500,000 shares of Ibotta at $30.15 on 2026-07-06, reducing holdings from 3,841,308 to 3,341,308 shares (-13.0%). This sale is noteworthy because the insider's prior five trades at IBTA were exclusively sells, all of which proved well-timed at the 90-day mark, with post-transaction returns ranging from -23.5% to -45.8%. Against current backdrop—the stock trading at $31.19, down 24.2% from its 52-week high of $41.14 and with IBTA posting negative fundamentals (net income of -$10,322,000, annual revenue decline of -6.8%, and P/E of 239.92)—the pattern of a 10% holder executing yet another sale after a track record of five prior well-timed exits at this ticker warrants attention. The consistent timing success across IBTA positions and the continued downward pressure on valuation metrics suggest the insider's sell discipline has tracked deterioration in the business rather than executed opportunistic profit-taking.

Bryan Leach (CEO) sold 28,231 shares for $993,965.83 on 2026-07-01/02 via 10b5-1 plan; retains 795,195 in derivative holdings

Bryan Leach, CEO and President, executed 12 separate sales totaling 28,231 shares for $993,965.83 across July 1-2, 2026, at a blended average price of $35.21. This transaction is part of a pre-arranged 10b5-1 trading plan and thus represents scheduled, non-discretionary activity. The current stock price of $33.00 is 19.8% below the 52-week high of $41.14, and the company reports a net loss of $10,322,000.00 in the latest quarter against revenue of $82,483,000.00, with annual revenue declining 6.8% year-over-year. While Leach's non-derivative holdings are fully liquidated, he retains significant derivative exposure through 795,195 shares in options and Class B stock vehicles.

Ibotta Director Lehrman sells 75.9K shares across 6 transactions for $2.4M, cutting holdings by -69.7%

Director Thomas D. Lehrman filed 6 separate sales totaling 75,907 shares for $2,362,946.52, reducing his position from 108,888 shares pre-transaction to 32,981 shares post-transaction — a -69.7% reduction in holdings. His cross-ticker track record across 20 prior sells shows an avg 90d return of -29.7% and a 90d well-timed rate of 95.00%, indicating a strong historical pattern of selling before subsequent price declines. His 5 prior sells at IBTA specifically, all on 2024-12-12, each produced 90-day returns between -42.7% and -43.8% at the 90-day mark, a consistent outcome at this ticker. The stock is currently -46.8% from its 52-week high, and IBTA reported a quarterly net income of $-10,322,000.00 alongside annual revenue growth of -6.8%, providing the fundamental backdrop against which this substantial director-level reduction occurs.

IBTA Director Lehrman sells 32,383 shares across 6 transactions for $1,048,127.47 at blended avg $32.37, retaining 52,556 shares.

Director Thomas D. Lehrman filed 6 separate sales totaling 32,383 shares for $1,048,127.47 at a blended average price of $32.37, reducing his holdings from 84,939 shares to 52,556 shares. His cross-ticker track record across 20 prior sells shows an avg 90-day return of -29.7% and a 90-day well-timed rate of 95.00%, indicating a strong historical pattern of selling ahead of price declines. His 5 prior sells at IBTA specifically — all on 2024-12-12 — were each well-timed at the 90-day mark, with 90-day returns ranging from -42.7% to -43.8%. The stock is currently trading at $30.81, already down -12.9% over the past 30 days and -50.9% from its 52-week high of $62.74, while Ibotta's latest quarter showed annual revenue growth of -6.8% and net income of $-10,322,000.00.

CRO Christopher Riedy acquired 276,041 shares of Ibotta, doubling holdings to 397,507 shares amid 70.8% drawdown from 52-week high.

Chief Revenue Officer Christopher Riedy purchased 276,041 shares on 2026-01-08, increasing his holdings by 227.3% from 121,466 to 397,507 shares. The purchase occurs at a significant discount to the 52-week high, with the current price of $21.83 representing a 70.8% decline from the $74.78 peak. Despite this material weakness, the company's fundamentals show resilience: annual revenue growth of 14.8% with recent quarterly revenue of $83,260,000, and a P/E ratio of 7.66 suggests valuation compression. The magnitude of this accumulation—more than doubling the executive's stake—combined with a 30-day price recovery of 2.0% against a steeper 90-day decline of 29.8%, warrants examination of whether company fundamentals diverge from recent price action.

Clark Jermoluk Founders Fund I sold 2,002,380 shares (99.4% of holdings) for $70,091,179.62 at IBTA on 2025-06-26.

A 10% owner divested nearly complete holdings through 4 separate sales totaling 2,002,380 shares for $70,091,179.62, reducing stake from 2,013,743 shares to 11,363 shares. The blended average sale price of $35.00 significantly exceeds the current price of $36.60, though the stock has declined -26.8% over 30 days and -52.4% from its 52-week high of $76.89. At the same ticker, this filer's prior 5 trades (all sells in late May and early June) show measurable 30-day returns of -26.3% and -27.0%, indicating the recent sell pattern occurred amid downward momentum. The company's fundamentals show positive trajectory (revenue growth +14.8%, P/E 12.84), but the near-complete exit by a founder-aligned fund represents a structural shift in insider positioning during a period of significant price deterioration.

CMO Richard I. Donahue sold 85,289 shares at $43.09 avg; now holds 199,773 shares; stock down 27.5% in 30 days, -47.7% from high.

Richard I. Donahue, Chief Marketing Officer, executed 2 separate sales totaling 85,289 shares for $3,674,767.08 at a blended average price of $43.09 on 2025-06-12, reducing his holdings by 29.9% to 199,773 shares. The current price of $41.34 is now 47.7% below the 52-week high of $78.98, and the stock has declined 27.5% over the past 30 days—a significant drawdown that post-dates this transaction. Reviewing his same-ticker history, Donahue's 3 prior sales at IBTA were all well-timed at the 90-day mark, suggesting a pattern of selling ahead of declines. However, the current stock weakness does not yet constitute a complete post-transaction valuation signal; investors should monitor whether the decline continues over the 90-day period following this June filing to assess whether the timing pattern holds.

Ibotta founder Clark Jermoluk sells 29,397 shares across 3 transactions totaling $1,469,739.64 at avg $50.00

Clark Jermoluk's Founders Fund I LLC executed 3 separate sales on 2025-06-03 and 2025-06-04, disposing of 29,397 shares (5.5% of pre-transaction holdings of 534,638 shares) for $1,469,739.64 at a blended average price of $50.00. The transactions occurred when the stock was trading near its 52-week range midpoint, with current price at $48.16 now down 50.4% from the 52-week high of $97.13. The insider's cross-ticker track record shows 0% win rate on prior sells (average 90-day return after sales was positive, indicating the stock went up after he sold), though this ticker-specific history cannot yet be measured given the sales are recent. The sales follow two other Ibota sales just days prior on 2025-05-28 and 2025-05-29, suggesting a pattern of liquidation activity by the founder over a concentrated period rather than an isolated transaction.

Ibotta founder Clark Jermoluk Founders Fund I LLC sells 23,543 shares for $1.2M; stock down 53.1% from 52-week high.

Clark Jermoluk Founders Fund I LLC executed 3 separate sales totaling 23,543 shares for $1,180,392.32 on 2025-05-28 and 2025-05-29, at a blended average price of $50.14, reducing holdings by 4.1% to 544,638 shares post-transaction. The stock currently trades at $49.99, down 53.1% from its 52-week high of $106.59, though it has gained 49.7% over the past 90 days and 2.4% over 30 days. The company reports revenue of $84.6M and net income of $555.0K in its latest quarter, with annual revenue growth of 14.8% and a P/E of 17.54. This sale occurs as the stock recovers from depressed levels but remains far below recent highs, and the insider retained a substantial stake of 544,638 shares post-transaction.

D.E. Shaw & Co sells 90,366 shares of IBTA at blended avg $33.36; stock down -68.2% from 52-week high of $109.90

D.E. Shaw & Co., a 10% owner, executed 6 separate sales totaling 90,366 shares for $3,014,345.79 on 2025-03-03, reducing holdings from 756,066 to 665,700 shares. The sales occurred at prices ranging from $32.89 to $34.79 (blended average $33.36), while the stock is now trading at $35.00 but has suffered a -68.2% decline from the 52-week high of $109.90. This large institutional disposition came amid severe downward momentum: the stock is down -50.0% over 30 days and -52.1% over 90 days. In the insider's same-ticker history at IBTA, all 5 prior buys (October 2024) were poorly timed, returning between -6.9% to -4.3% at 30 days and -1.9% to -0.3% at 90 days with a 0% 90-day win rate. The current sell appears to occur at a point of substantial valuation erosion but does not necessarily represent prescient market timing given the stock's extreme volatility and the insider's prior unsuccessful buy timing at this ticker.